clinical trial · NCT06318169
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
89bio, Inc.·phase3·recruiting·n = 1,350
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisPegozaferminPlacebo
brief summary
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
started
Mar 13, 2024
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
May 5, 2026
official title
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol